XML 66 R44.htm IDEA: XBRL DOCUMENT
v3.20.4

Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended
--- | --- | ---
Dec. 31, 2020 | Sep. 30, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Dec. 31, 2019 | Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018
Revenue related to Sanofi agreement: |  |  |  |  |  |  |  |  |  |  |
Total | $ 25,800 | $ 57,763 | $ 21,553 | $ 13,076 | $ 54,851 | $ 21,958 | $ 17,548 | $ 8,071 | $ 118,192 | $ 102,428 | $ 84,452
Novartis Institutes For Bio Medical Research Inc | Research services |  |  |  |  |  |  |  |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |  |  |  |  |  |  |  |
Total |  |  |  |  |  |  |  |  | 1,100 |  |
Novartis Institutes For Bio Medical Research Inc | Recognition of upfront fee |  |  |  |  |  |  |  |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |  |  |  |  |  |  |  |
Total |  |  |  |  |  |  |  |  | 4,100 |  |
Biogen MA Inc | Research services |  |  |  |  |  |  |  |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |  |  |  |  |  |  |  |
Total |  |  |  |  |  |  |  |  | 6,500 |  |
Biogen MA Inc | Recognition of upfront fee |  |  |  |  |  |  |  |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |  |  |  |  |  |  |  |
Total |  |  |  |  |  |  |  |  | 21,400 |  |
Kite Pharma, Inc. ("Kite") |  |  |  |  |  |  |  |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |  |  |  |  |  |  |  |
Total |  |  |  |  |  |  |  |  | 28,608 | 34,350 | 25,517
Kite Pharma, Inc. ("Kite") | Research services |  |  |  |  |  |  |  |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |  |  |  |  |  |  |  |
Total |  |  |  |  |  |  |  |  | 3,562 | 9,373 | 6,972
Kite Pharma, Inc. ("Kite") | Recognition of upfront fee |  |  |  |  |  |  |  |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |  |  |  |  |  |  |  |
Total |  |  |  |  |  |  |  |  | 25,046 | 24,977 | 18,545
Pfizer, Giroctocogene Fitelparvovec |  |  |  |  |  |  |  |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |  |  |  |  |  |  |  |
Total |  |  |  |  |  |  |  |  | 34,449 | 39,359 | 37,810
Pfizer, Giroctocogene Fitelparvovec | Recognition of upfront fee |  |  |  |  |  |  |  |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |  |  |  |  |  |  |  |
Total | $ 8,700 |  |  |  |  |  |  |  | 3,111 | 15,697 | 37,810
Pfizer, Giroctocogene Fitelparvovec | Milestone achievement |  |  |  |  |  |  |  |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |  |  |  |  |  |  |  |
Total |  |  |  |  |  |  |  |  | 31,338 | 23,662 | 0
Pfizer C9ORF72 |  |  |  |  |  |  |  |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |  |  |  |  |  |  |  |
Total |  |  |  |  |  |  |  |  | 12,985 | 1,827 | 2,188
Pfizer C9ORF72 | Recognition of upfront fee |  |  |  |  |  |  |  |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |  |  |  |  |  |  |  |
Total |  |  |  |  |  |  |  |  | 7,985 | 1,827 | 2,188
Pfizer C9ORF72 | Milestone achievement |  |  |  |  |  |  |  |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |  |  |  |  |  |  |  |
Total |  |  |  |  |  |  |  |  | 5,000 | 0 | 0
Sanofi |  |  |  |  |  |  |  |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |  |  |  |  |  |  |  |
Total |  |  |  |  |  |  |  |  | 5,322 | 22,680 | 13,516
Sanofi | Research services |  |  |  |  |  |  |  |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |  |  |  |  |  |  |  |
Total |  |  |  |  |  |  |  |  | 4,823 | 6,367 | 9,503
Sanofi | Recognition of upfront fee |  |  |  |  |  |  |  |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |  |  |  |  |  |  |  |
Total |  |  |  |  |  |  |  |  | 298 | 3,494 | 4,013
Sanofi | Milestone achievement |  |  |  |  |  |  |  |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |  |  |  |  |  |  |  |
Total |  |  |  |  |  |  |  |  | $ 201 | $ 12,819 | $ 0

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenuesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sgmo_ResearchServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_PfizerGiroctocogeneFitelparvovecMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sgmo_MilestoneAchievementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_SanofiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |